BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 18, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2014

View Archived Issues

Novel FabI inhibitors with promising activity against staphylococcal infections

Read More

Cleave Biosciences initiates phase I trial of CB-5083 in patients with solid tumors

Read More

Arisaph Pharmaceuticals initiates phase II study of ARI-3037-MO in hypertriglyceridemia

Read More

Uncovering de novo mutations that underscore epileptic encephalopathies

Read More

FDA grants Vivolux clearance to conduct phase I/II trial of VLX-1570

Read More

Updated phase I results for MSC-2156119J in advanced solid tumors

Read More

Deciphera Pharmaceuticals patents novel agents for cancer and other disorders

Read More

Novel pyrrolotriazines disclosed by Bristol-Myers Squibb for arrhythmia

Read More

Aurigene Discovery Technologies designs new NAmPRTase inhibitors

Read More

Takeda Pharmaceutical divulges novel ROR-gamma antagonists

Read More

Scientists at Roche synthesize novel autotaxin inhibitors

Read More

FDA approves Uceris rectal foam for induction of remission of distal ulcerative colitis

Read More

MedImmune in-licenses Shionogi's ACS biologic research program

Read More

PET imaging of Abeta plaques using a novel 89Zr-labeled MAb

Read More

Striverdi Respimat inhalation spray now available in the U.S.

Read More

E-6005 shows efficacy and safety in early clinical studies in patients with atopic dermatitis

Read More

Amgen reports topline results from phase III study of adalimumab biosimilar in psoriasis

Read More

Teva Pharmaceutical begins rolling NDA for CEP-33237

Read More

Ruthigen begins phase I/II trial of RUT-5860

Read More

Patient enrollment under way in phase II trial of VPI-2690B in diabetic nephropathy

Read More

Nabriva Therapeutics granted FDA QIDP and fast track status for lefamulin

Read More

Bristol-Myers Squibb to begin a phase I/II study of BMS-986012 in small cell lung cancer

Read More

FDA grants priority review to Lucentis submission for diabetic retinopathy

Read More

RedoxTherapies licenses Vernalis' vipadenant for immuno-oncology applications

Read More

Regen BioPharma files IND application for autologous dendritic cell therapy for breast cancer

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing